A detailed history of Mv Capital Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mv Capital Management, Inc. holds 192 shares of VRTX stock, worth $96,470. This represents 0.01% of its overall portfolio holdings.

Number of Shares
192
Previous 192 -0.0%
Holding current value
$96,470
Previous $89,000 -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$392.81 - $485.53 $3,535 - $4,369
9 Added 4.92%
192 $89,000
Q1 2024

Apr 18, 2024

SELL
$407.69 - $446.08 $4,892 - $5,352
-12 Reduced 6.15%
183 $76,000
Q4 2023

Jan 29, 2024

BUY
$343.0 - $410.68 $5,488 - $6,570
16 Added 8.94%
195 $79,000
Q3 2023

Nov 07, 2023

BUY
$338.18 - $362.46 $3,719 - $3,987
11 Added 6.55%
179 $62,000
Q2 2023

Aug 03, 2023

BUY
$314.42 - $351.91 $3,144 - $3,519
10 Added 6.33%
168 $59,000
Q1 2023

Apr 26, 2023

BUY
$283.23 - $323.1 $3,115 - $3,554
11 Added 7.48%
158 $49,000
Q4 2022

Jan 27, 2023

BUY
$285.76 - $321.48 $285 - $321
1 Added 0.68%
147 $0
Q3 2022

Oct 24, 2022

BUY
$273.83 - $305.53 $6,571 - $7,332
24 Added 19.67%
146 $42,000
Q2 2022

Jul 19, 2022

SELL
$234.96 - $292.55 $234 - $292
-1 Reduced 0.81%
122 $34,000
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $6,864 - $8,090
31 Added 33.7%
123 $32,000
Q4 2021

Feb 02, 2022

BUY
$177.01 - $223.45 $1,062 - $1,340
6 Added 6.98%
92 $20,000
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $13,785 - $15,427
76 Added 760.0%
86 $16,000
Q2 2021

Aug 03, 2021

BUY
$187.49 - $221.1 $562 - $663
3 Added 42.86%
10 $2,000
Q1 2021

May 12, 2021

BUY
$207.02 - $241.31 $1,449 - $1,689
7 New
7 $2,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mv Capital Management, Inc. Portfolio

Follow Mv Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mv Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mv Capital Management, Inc. with notifications on news.